Yili Chuannig Biotechnology Co Ltd
301301
Company Profile
Business description
Yili Chuannig Biotechnology Co Ltd adopts the most advanced and mature international biological fermentation, chemical extraction, enzymatic hydrolysis, control and energy saving, and environmental protection technology. The main products of the company include erythromycin thiocyanate, cephalosporin intermediates, penicillin intermediates, and crude ursodeoxycholic acid.
Contact
No. 516, Almatua Village
Yining Park, Horgos Economic Development Zone
Xinjiang
Ili835000
CHNT: +86 9998077777
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
3,126
Stocks News & Analysis
stocks
The ASX player evolving into a defensive haven
A well-timed simplification journey as boring evolves back in vogue.
stocks
12 picks for an income portfolio - Q1 2026 update
Passive income growth continues to exceed my target.
stocks
Strong guidance from undervalued ASX share
Shares surged after the announcement of first half fiscal 2026 guidance.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,174.10 | 12.00 | 0.13% |
| CAC 40 | 8,340.59 | 84.54 | -1.00% |
| DAX 40 | 24,372.60 | 329.64 | -1.33% |
| Dow JONES (US) | 49,447.43 | 868.71 | 1.79% |
| FTSE 100 | 10,611.03 | 56.60 | -0.53% |
| HKSE | 26,361.07 | 200.74 | 0.77% |
| NASDAQ | 24,468.48 | 365.78 | 1.52% |
| Nikkei 225 | 58,824.89 | 693.45 | -1.17% |
| NZX 50 Index | 12,915.45 | 150.61 | -1.15% |
| S&P 500 | 7,126.06 | 84.78 | 1.20% |
| S&P/ASX 200 | 8,953.30 | 13.60 | 0.15% |
| SSE Composite Index | 4,082.13 | 30.70 | 0.76% |